Why Does a Reduced Dose of a JAK Inhibitor Improve Anemia?

Dr. Naval Daver from MD Anderson Cancer Center responds to Patient Power community member Jean’s question, “Why does a reduced dosage of ruxolitinib (Jakafi) allow red blood cells to improve the level of anemia?” Dr. Daver shares an in-depth response, including ad explanation of the JAK-STAT pathway and results of a clinical trial for a reduced dosage of ruxolitinib (Jakafi) designed to reverse anemia.

The Ask the Expert series is sponsored through an educational grant to the Patient Empowerment Network from Incyte Corporation.

This article was originally published March 31, 2016 and most recently updated September 11, 2019.
© 2024 HealthCentral LLC. All rights reserved.

More on Myeloproliferative Neoplasms